The Northern Territory prison population comprises 92% Indigenous Australians and 88% smokers. The NT prison-smoking ban creates a population-wide abstinence. We aim to extend this period of abstinence into the community.
Rationale
The IDAT Program, established under the Drug and Alcohol Treatment Act 2007 of New South Wales, aims to “provide short-term care, with an involuntary supervised withdrawal component, to protect the health and safety of people with severe substance dependence who have experienced, or are at risk o
This randomised double-blind placebo-controlled study, led by St Vincent's Hospital Sydney, aims to examine the safety and efficacy of lisdexamfetamine in the treatment of adults with severe methamphetamine (MA) dependence.
NADA, under funding provided by the NSW Ministry for Health, is conducting a project to develop a set of treatment service specifications for the NSW specialist NGO drug and alcohol sector.
This innovative, integrated care project was implemented in the South Eastern Sydney Local Health District to improve integration of services provided to those who are frequent attenders to the Emergency Department and have drug and alcohol use disorders.
This project will conduct the first-ever outpatient RCT to test the efficacy, safety and cost-effectiveness of the pharmaceutical cannabinoid nabiximols (Sativex®) for treating cannabis dependence.
This project undertakes research to understand the pathways of vulnerable adolescents and the role of the Ted Noffs Program for Adolescent Life Management (PALM) in assisting young people to get their lives back on track.
Tobacco smoking is a leading cause of preventable disease and death. Smoking rates are higher among disadvantaged Australians and facilitating smoking cessation in this group is a national health priority.
Overdose is a common event in the lives of opioid users, and is the leading cause of death in this population. Overdose risk is particularly elevated during the 4 weeks following release from prison.
This study aimed to examine the feasibility of agonist maintenance treatment for the major psychoactive drug classes: opioids, nicotine, benzodiazepines, cannabis, psychostimulants and alcohol.
